Save the Cord Foundation and WellSky are proud to welcome Dr. John Wagner, as our featured speaker for our next edition of Share the Science on July 22nd, 2021 2pm ET / 11am PT. Join us to hear Dr. Wagner discuss his research using umbilical cord blood-derived regulatory T Cells (Tregs) to combat Graft versus Host Disease (GvHD). RECORDING NOW AVAILABLE. Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field. As always, we invite both health professionals and the general public to join us for this unique online educational series. Learn more about this exciting educational series here. Preventing GvHD with Regulatory T Cells (Tregs)Join us to hear pioneering researcher John Wagner, M.D. as he shares some of his latest work involving potential treatment of autoimmunity and graft-versus-host disease (GVHD). Infection and relapse are the principal obstacles to successful use of allogeneic hematopoietic stem cell transplantation. Prolonged immunodeficiency is a major cause of infection and relapse, particularly in those with high-risk disease, older age, use of in vivo and ex vivo T cell depletion, HLA mismatch, and after the development of acute and chronic GVHD. Trials have demonstrated that the infusion of umbilical cord blood (UCB) derived regulatory T cells (Tregs) could effectively prevent GVHD. Join Dr. Wagner as he also shares how thymic progenitor cells (Pro-Ts) can repair damaged immune systems, and how UCB can reliably provide large numbers of Pro-Ts suitable for clinical use. SHARE THE SCIENCE with John Wagner, M.D. Founding Director of the Institute of Cell, Gene and Immunotherapeutics at the University of Minnesota "Combatting GVHD with UCB-derived regulatory T cells" Free webinar. Open to the public. Thursday, July 22nd at 2 pm ET / 11am PT RECORDING NOW AVAILABLE About the speaker
We wish to thank Dr. John Wagner for volunteering his time to speak on
Share the Science and sharing his valuable insight on the use of cord blood-derived Tcells (Tregs) to combat GvHD. We also wish to also thank our generous sponsor and partner for this event, WellSky Health, who continue to support cord blood education through our “Share the Science” series. Save the Cord Foundation and WellSky are proud to welcome Dr. Camillo Ricordi, as our featured speaker for our next edition of Share the Science on June 10th, 2021 2pm ET / 11am PT. Join us to hear Dr. Ricordi discuss a recent study using cord blood-derived mesenchymal stem cell infusions to treat COVID-19 patients suffering from the most severe conditions. RECORDING NOW AVAILABLE. Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field. As always, we invite both health professionals and the general public to join us for this unique online educational series. Learn more about this exciting educational series here. Cord Blood MSCs for COVID-19?Dr. Ricordi and his team began to document their ground-breaking study using cord blood-derived MSCs to treat COVID-19 patients beginning in the spring of 2020, at the height of the pandemic. It was a moment of incredible challenges for healthcare professionals around the globe. Everyone was desperate to understand this new, mysterious disease. Cases were increasing exponentially everywhere. News agencies in every country began to count the daily death rates. Many countries decided to lockdown. The new normal was bleak, but doctors and nurses on the front lines were not giving up. They were looking for new ways to treat COVID-19 patients. Building on a very small study in China, Dr. Ricordi and his team at the University of Miami led the battle against COVID-19 with their innovative study using cord blood-derived MSCs to potentially improve recovery and prevent deaths in the most severely affected patients. The results of this study were very encouraging and have laid the groundwork for further studies using umbilical cord-derived mesenchymal stem cell infusions and other similar techniques to potentially treat COVID-19. The group published their results in January 2021 in Stem Cells Translational Medicine: "Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial" Join us on June 10th to hear Dr. Ricordi, the study’s senior author, as he reviews the data and the potential for stem cells to be used more broadly to treat COVID-19 and similar respiratory infections. Highlights from the study:
SHARE THE SCIENCE with Camillo Ricordi, MD Director of the Diabetes Research Institute and the Cell Transplant Program at the University of Miami, Florida "Reducing risks of COVID-19 with Mesenchymal Stem Cells" Free webinar. Open to the public. Thursday, June 10th at 2 pm ET / 11am PT RECORDING NOW AVAILABLE. *Note: You will be directed to register via WellSky, our partner for this event. About the speaker
We wish to thank Dr. Camillo Ricordi for volunteering his time to speak on
Share the Science and sharing his valuable insight on the use of cord blood-derived mesenchymal stem cells. We also wish to also thank our generous sponsor and partner for this event, WellSky Health, who continue to support cord blood education through our “Share the Science” series. Save the Cord Foundation and WellSky are proud to welcome Dr. Shernan Holtan, as our featured speaker for our next edition of Share the Science on May 20th, 2021 2pm ET / 11am PT. Join us to hear Dr. Holtan discuss the potential costs of healthcare long-term for cord blood transplant recipients. Share the Science is a free webinar series focused on the cord blood industry and the latest research in this field. As always, we invite both health professionals and the general public to join us for this unique online educational series. Learn more about this exciting educational series here. RECORDING NOW AVAILABLE. Cord blood transplants cheaper long term?Discover how umbilical cord blood may reduce the visits, lab studies, and medications required after hematopoietic stem cell transplants. Recipients of allogeneic hematopoietic cell transplantation (HCT) require substantial follow-up care after transplant. Now, data from 1,077 consecutive adult allogeneic HCT recipients at the University of Minnesota Medical School suggest that HCTs involving umbilical cord blood (UCB) had the lowest overall health care burden in the five years after transplant. The study also looked at HCTs with peripheral blood stem cells and bone marrow. The recipients of UCB had a lower long-term health care burden as measured by the number of:
SHARE THE SCIENCE with Shernan Holtan, MD Associate Professor of Medicine in the Division of Hematology, Oncology, and Transplantation - University of Minnesota Medical School "Reducing the Costs of Post-Transplant Care with Cord Blood" Free webinar. Open to the public. Thursday, May 20th at 2 pm ET / 11am PT RECORDING NOW AVAILABLE About the speaker
We wish to thank Dr. Shernan Holtan for volunteering her time to speak on
Share the Science and sharing her valuable insight on the cost of healthcare for stem cell transplant recipients. We also wish to also thank our generous sponsor and partner for this event, WellSky Health, who continue to support cord blood education through our “Share the Science” series. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
March 2023
Categories |